DOE Patents title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Identification of cancer protein biomarkers using proteomic techniques

Abstract

The claimed invention describes methods to diagnose or aid in the diagnosis of cancer. The claimed methods are based on the identification of biomarkers which are particularly well suited to discriminate between cancer subjects and healthy subjects. These biomarkers were identified using a unique and novel screening method described herein. The biomarkers identified herein can also be used in the prognosis and monitoring of cancer. The invention comprises the use of leptin, prolactin, OPN and IGF-II for diagnosing, prognosis and monitoring of ovarian cancer.

Inventors:
; ;
Issue Date:
Research Org.:
Yale Univ., New Haven, CT (United States)
Sponsoring Org.:
USDOE
OSTI Identifier:
1493331
Patent Number(s):
10168334
Application Number:
15/268,134
Assignee:
Yale University (New Haven, CT)
Patent Classifications (CPCs):
C - CHEMISTRY C12 - BIOCHEMISTRY C12Q - MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
G - PHYSICS G01 - MEASURING G01N - INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
DOE Contract Number:  
FG02-ER63462
Resource Type:
Patent
Resource Relation:
Patent File Date: 2016 Sep 16
Country of Publication:
United States
Language:
English
Subject:
60 APPLIED LIFE SCIENCES

Citation Formats

Mor, Gil G., Ward, David C., and Bray-Ward, Patricia. Identification of cancer protein biomarkers using proteomic techniques. United States: N. p., 2019. Web.
Mor, Gil G., Ward, David C., & Bray-Ward, Patricia. Identification of cancer protein biomarkers using proteomic techniques. United States.
Mor, Gil G., Ward, David C., and Bray-Ward, Patricia. Tue . "Identification of cancer protein biomarkers using proteomic techniques". United States. https://www.osti.gov/servlets/purl/1493331.
@article{osti_1493331,
title = {Identification of cancer protein biomarkers using proteomic techniques},
author = {Mor, Gil G. and Ward, David C. and Bray-Ward, Patricia},
abstractNote = {The claimed invention describes methods to diagnose or aid in the diagnosis of cancer. The claimed methods are based on the identification of biomarkers which are particularly well suited to discriminate between cancer subjects and healthy subjects. These biomarkers were identified using a unique and novel screening method described herein. The biomarkers identified herein can also be used in the prognosis and monitoring of cancer. The invention comprises the use of leptin, prolactin, OPN and IGF-II for diagnosing, prognosis and monitoring of ovarian cancer.},
doi = {},
journal = {},
number = ,
volume = ,
place = {United States},
year = {2019},
month = {1}
}

Works referenced in this record:

The role of Osteopontin in tumor metastasis
journal, October 2004


Osteopontin is a potential target gene in mouse mammary cancer chemoprevention by Se-methylselenocysteine
journal, July 2004


Multiplexed protein profiling on microarrays by rolling-circle amplification
journal, April 2002


Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma
journal, October 2004


Isolated ductal fluid sample
patent, November 2003


Utility of osteopontin as a biomarker in recurrent epithelial ovarian cancer
journal, May 2004


Identification of cancer protein biomarkers using proteomic techniques
patent, March 2015


Progress and Challenges in Screening for Early Detection of Ovarian Cancer
journal, February 2004


Prolactin acts as a potent survival factor for human breast cancer cell lines
journal, June 2004


Elevated leptin concentrations in pregnancy and lactation: Possible role as a modulator of substrate utilization
journal, August 1999


The metastasis gene osteopontin: a candidate target for cancer therapy
journal, December 2001


Enhanced Expression of Leptin and Leptin Receptor (OB-R) in Human Breast Cancer
journal, July 2004


Expression of Leptin Receptors and Potential Effects of Leptin on the Cell Growth and Activation of Mitogen-Activated Protein Kinases in Ovarian Cancer Cells
journal, January 2005


Plasma Prolactin Concentrations and Risk of Postmenopausal Breast Cancer
journal, September 2004


Ovarian dysgerminoma showing high serum levels and positive immunostaining of placental alkaline phosphatase and neuron-specific enolase associated with elevation of serum prolactin level
journal, October 1998


Methods and compositions for diagnosing and monitoring transplant rejection
patent, April 2006


Prolactin increases HO-1 expression and induces VEGF production in human macrophages
journal, January 2004


Gene expression in bladder tumors
patent, August 2005


Three Biomarkers Identified from Serum Proteomic Analysis for the Detection of Early Stage Ovarian Cancer
journal, August 2004


Ovarian cancer screening
journal, August 2003


Gene expression in bladder tumors
patent, January 2002


Leptin directly stimulates aromatase activity in human luteinized granulosa cells
journal, August 1999


Circulating levels of insulin-like growth factor-II and IGF-binding protein 3 in cervical cancer
journal, December 2003


Fasting Ghrelin Levels in Physically Active Women: Relationship with Menstrual Disturbances and Metabolic Hormones
journal, July 2004


Leptin expression in colorectal and breast cancer patients.
journal, April 2000


Therapeutic Implications of Immune-endocrine Interactions in the Critically Ill Patients
journal, June 2004


Diagnostic marker for tumor hypoxia and prognosis
patent-application, March 2003


Prolactin as a tumour marker in cancer of the cervix
journal, January 1998


Differential gene expression profiling in human brain tumors
journal, February 2001


Multiple Kinase Cascades Mediate Prolactin Signals to Activating Protein-1 in Breast Cancer Cells
journal, December 2004


Elevation of Multiple Serum Markers in Patients With Stage I Ovarian Cancer
journal, November 1993


Osteopontin as an Adjunct to CA125 in Detecting Recurrent Ovarian Cancer
journal, May 2004


Cancer screening in a high risk population: a clinical trial
journal, April 2001


Detection of neoplasms by hormonal tumor stimulation test
patent, December 1996


Identification of cancer protein biomarkers using proteomic techniques
patent, October 2016


Method for inhibiting neoplastic disease in mammals
patent, June 2000


Identification of cancer protein biomarkers using proteomic techniques
patent, February 2010


Obesity, adipocytokines, and insulin resistance in breast cancer
journal, August 2004


Ovarian cancer screening
journal, August 2004


Diagnostic Markers for Early Detection of Ovarian Cancer
journal, February 2008


Methods and compositions for diagnosing and monitoring transplant rejection
patent, June 2007


The Functional and Clinical Roles of Osteopontin in Cancer and Metastasis
journal, November 2001


Menstrual Cycle Dependent Variability for Serum Tumor Markers CEA, AFP, CA 19-9, CA 125 and CA 15-3 in Healthy Women
journal, January 1999


Ghrelin inhibits leptin- and activation-induced proinflammatory cytokine expression by human monocytes and T cells
journal, July 2004


Use of serum prolactin for monitoring the therapeutic response in ovarian malignancy
journal, September 1991


Downregulation of long-form prolactin receptor mRNA during prolactin-induced luteal regression
journal, August 2000


Osteopontin as a Potential Diagnostic Biomarker for Ovarian Cancer
journal, April 2002


Role of osteopontin in tumour progression
journal, April 2004


Use of proteomic patterns in serum to identify ovarian cancer
journal, February 2002


Multiplexed Immunobead-Based Cytokine Profiling for Early Detection of Ovarian Cancer
journal, April 2005


Serum Vascular Endothelial Growth Factor and Serum Leptin in Patients with Cervical Cancer
journal, April 2002


Differential Gene Expression in Chemically Induced Mouse Lung Adenomas
journal, January 2003


Serum protein markers for early detection of ovarian cancer
journal, May 2005